MPLT (MapLight Therapeutics) Total Assets: $418.79 Mil (As of Mar. 2026)


MPLT MapLight Therapeutics Inc MPLT
14 GF Score
Price $37.11
! 4 Warning Signs
View Full Analysis

What is MapLight Therapeutics Total Assets?

MapLight Therapeutics MPLT +3.09% 14 Total Assets is $418.79 Mil as of Mar. 2026. GuruFocus rates MPLT with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

MapLight Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $418.79 Mil.

During the past 12 months, MapLight Therapeutics's average Total Assets Growth Rate was 520.20% per year. During the past 3 years, the average Total Assets Growth Rate was 145.90% per year.

During the past 4 years, MapLight Therapeutics's highest 3-Year average Total Assets Growth Rate was 145.90%. The lowest was 145.90%. And the median was 145.90%.

Total Assets is connected with ROA %. MapLight Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -54.03%. Total Assets is also linked to Revenue through Asset Turnover. MapLight Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

MapLight Therapeutics  (NAS:MPLT) Total Assets Explanation

Total Assets is connected with ROA %.

MapLight Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-242.672/( (479.512+418.788)/ 2 )
=-242.672/449.15
=-54.03 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

MapLight Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (479.512+418.788)/ 2 )
=0/449.15
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

MapLight Therapeutics Total Assets Related Terms

MapLight Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for MapLight Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MapLight Therapeutics Total Assets Chart

MapLight Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Assets
39.39 91.41 136.92 479.51

MapLight Therapeutics Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 111.57 84.12 257.22 479.51 418.79
MPLT
14GF Score
MapLight Therapeutics Inc MPLT
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MapLight Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

MapLight Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=458.372+21.14
=479.51

MapLight Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=399.834+18.954
=418.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $418.79 Mil mean?
MapLight Therapeutics (MPLT) has a Total Assets of $418.79 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on MapLight Therapeutics and its competitors.
Is MapLight Therapeutics' Total Assets too high?
MapLight Therapeutics' current Total Assets is $418.79 Mil. Overall, MapLight Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MapLight Therapeutics' Total Assets compare to COAG and CAPR?
MapLight Therapeutics' Total Assets of $418.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on MapLight Therapeutics and its competitors. MapLight Therapeutics's current Total Assets is $418.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MapLight Therapeutics stock overvalued right now?
MapLight Therapeutics (MPLT) has a current Total Assets of $418.79 Mil. The current Total Assets is $418.79 Mil. MapLight Therapeutics' overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For MapLight Therapeutics (MPLT), the current Total Assets is $418.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MapLight Therapeutics Business Description

Address 800 Chesapeake Drive, Redwood City, CA, USA, 94063
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
14GF Score

Get the complete analysis for MPLT

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.11
Price